Background
==========

In 2011, the International Diabetes Federation (IDF) estimated that about 366 million people worldwide have diabetes mellitus (DM). 80% of these people live in the low and middle income countries where tuberculosis (TB) is highly prevalent \[[@B1]\]. According to the World Health Organisation (WHO), there were an estimated 8.8 million incident cases of TB globally in 2010 \[[@B2]\].

Currently, both TB and DM are of great public health importance globally especially in Sub Saharan Africa (SSA) due to the converging epidemics of both communicable and non communicable diseases. With a prevalence rate of TB of 193/100,000 in 2010, Uganda is one of the high burden TB countries in SSA \[[@B3]\]. There is also an observed trend of increasing prevalence of DM in Uganda. The estimated prevalence according to the International Diabetes Federation in 2010 was 2.2% \[[@B4]\].

Recent evidence advocates for bi-directional screening and care of TB and DM patients. This is because both morbidities adversely affect each other \[[@B5]\] and currently, there is plausible evidence from different studies to support the strong association between DM and TB \[[@B6],[@B7]\]. Diabetic patients have impaired cell mediated immunity, renal failure, micronutrient deficiency and pulmonary microangiopathy, all of which increase their propensity to develop TB \[[@B8]\]. DM is also known to alter the clinical presentation of TB and its outcomes in terms of delayed sputum/culture conversion, case fatality and treatment failure \[[@B9]\].

TB co-infection is associated with poor glycemic control among DM patients. Reactionary hyperglycemia often accompanies chronic infections like TB due to the increased pro-inflammatory state and release of counter-regulatory stress hormones like epinephrine, cortisol and glucagon that are antagonistic of insulin \[[@B10]\]. Rifampicin, a very potent anti TB drug has also been shown to induce a transient early phase hyperglycemia owing to augmentation of intestinal glucose absorption \[[@B11]\].

This study sought to determine the prevalence of DM and the associated clinical factors among the adult TB patients admitted on the pulmonology wards of Mulago national referral and teaching hospital, Uganda.

Methods
=======

Study site description
----------------------

Mulago national referral and teaching hospital is located in Kampala, the capital city of Uganda and serves a population of about 2 million people. It is a 1,500 bed facility serving as a national referral hospital and teaching hospital for Makerere University College of Health Sciences, Uganda. The hospital has two adult pulmonology wards primarily for admission of patients with the varied pulmonary medical conditions like TB.

Study methods
-------------

This was a cross sectional study in which adult patients with a confirmed diagnosis of TB admitted on the pulmonology wards of Mulago hospital were consecutively recruited during weekdays of the study period of September 2011 up to February 2012.

Patients enrolled into the study were ≥18 years of age, admitted on the pulmonology wards during the study periods and had a confirmed diagnosis of TB. All patients who were on anti TB drugs and those who could not offer informed consent were excluded from the study.

A confirmed diagnosis of TB was made if the patient presented with clinical symptoms suggestive of TB and at least one of the following: a positive sputum smear on Ziehl Nielsen or flourochrome (Auramine-O) stain for acid fast bacilli (AFB), a positive Xpert/RIF-TB test result, a positive sputum culture for TB and a histological diagnosis of TB on lymph node or pleural biopsy.

Data collection
---------------

All patients gave informed consent prior to enrolment into the study. Information on the socio-demographic characteristics, medical history and laboratory variables of the consented eligible study participants was collected using pre-coded questionnaire forms. All patients underwent anthropometric measurements for estimation of the body mass index (BMI).

A capillary blood sample was obtained for measurement of the random blood sugar (RBS) level using a One Touch Ultra® glucometer from Johnson and Johnson Company, United Kingdom. Blood was also drawn for measurement of the serum albumin, renal function tests (serum urea and creatinine) for calculation of the glomerular filtration rate (GFR), liver function tests (alanine transaminase (ALT) and alkaline phosphatase (ALP) levels), HIV serology and CD4 counts. The normal values for the above tests were: serum albumin: 35--50 g/L, GFR: 90--120 ml/min/1.73 m \[[@B2]\], ALT: 0-80U/L and ALP: 30--129 U/L. All the above tests were done prior to initiation of anti TB drugs. The cockroft Gault formula below was used to estimate the glomerular filtration rate (GFR). Normal GFR was defined as an estimated GFR of ≥ 90 ml/min/1.73 m \[[@B2]\].

GFR = \[(140-Age in years) × body weight in kg/ serum creatinine in mg/dl × 72\] × 0.85 if female.

The diagnosis of DM was made basing on the recent American Diabetes Association (ADA) guidelines of a random or casual blood sugar level ≥ 200mg/dl in the presence of the classical symptoms of DM \[[@B12]\]. The classical symptoms of DM include: polyuria, polydipsia, polyphagia, generalised body weakness and progressive weight loss. Type 2 diabetic patients were defined as patients aged ≥30 years on oral hypoglycaemic drugs and/or insulin therapy while type 1 diabetic patients were those aged \< 30 years on insulin monotherapy.

Statistical analysis
--------------------

Data was entered into EPI-INFO Version 6 and analysed using SPSS version 14. Patient's characteristics were summarised with proportions and the continuous variables expressed in mean and standard deviation for normally distributed variables.

To determine associations between the different factors and RBS levels, the outcome variable, bivariate analyses using chi-square test was performed. For variables in which the cell values were less than 5, the Fischer's exact test was used instead. Continuous variables were categorised into 2 groups based on the normal cut off values and then compared. Age was categorised into 2 groups using the cut of value of the average age.

Binary logistic regression analysis was performed to determine which factors were independently associated with DM among the study participants. Multivariate analysis was then performed and variables considered were those which had a conservatively set cut off p-value of \<0.3 on bivariate analysis. A p-value of \<0.05 and confidence intervals not including 1 were considered to be statistically significant.

Using the prevalence of 13.2% of DM among TB patients in Indonesia \[[@B13]\], with 80% power and a two-sided α \< 0.05, a sample size of 176 study subjects was obtained. However, we enrolled 260 patients for the study.

Ethical consideration
---------------------

This study was approved by the department of Internal Medicine, Makerere College of Health Sciences and the Makerere University School of Medicine research and ethics committee, Uganda.

Results
=======

Socio-demographic, clinical and laboratory characteristics of the patients
--------------------------------------------------------------------------

Of the 260 study participants enrolled, majority were male (n=146, 56.2%). The mean age of the study participants was 34.5 years (S.D 9.5). The youngest participant was 18 years and the eldest was 65 years. HIV co-infection was documented in 280 (80%) participants with 78% of them having CD4 counts \< 200 cells/mm \[[@B3]\]. The mean BMI was 17.4 kg/m \[[@B2]\]. Sixty three (23.2%) and 197 (75.8%) participants had extra pulmonary TB (EPTB) and pulmonary TB (PTB) respectively. Fifty (19.2%) of the participants had TB relapse (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}).

###### 

Baseline socio-demographic factors and clinical characteristics of the study participants

  **Characteristic**                                                               **Frequency (n=260)**   **Percentage (%)**
  ---------------------------------------------------------- --------------------- ----------------------- --------------------
  **Age (years) Mean (\*SD) 34.7(9.5)**                                                                     
                                                             18-35                 154                     59.2
                                                             36-50                 91                      35
                                                             \>50                  15                      5.8
  **Gender**                                                 Male                  146                     56.2
                                                             Female                114                     43.8
  **Place of residence**                                     Rural                 77                      29.6
                                                             Urban                 183                     70.4
  **Level of education**                                     No formal education   18                      6.9
                                                             Primary level         168                     64.6
                                                             Secondary level       54                      20.8
                                                             Tertiary level        20                      7.7
  **Occupation**                                             Unemployed            58                      22.3
                                                             Self employed         34                      13.1
                                                             Unskilled             147                     56.5
                                                             Skilled               21                      8.1
  **Smoking status**                                         Former smokers        66                      25.4
                                                             Non smokers           194                     74.6
  **HIV infection**                                          Positive              208                     80
  **On HAART**                                               Yes                   61                      29
  **Known diabetes mellitus**                                Yes                   5                       1.9
  **History of TB treatment.**                               No                    207                     79.6
  **Karnofsky score (%) Mean (SD) 61.5 (14.3)**                                                             
                                                             \<70%                 132                     50.8
  **Category of TB**                                         PTB                   197                     75.8
  **Body mass index, kg/m**^**2**^**Mean (SD) 17.4 (2.5)**                                                  
                                                             \<18.5                181                     69.6

\* SD- Standard deviation.

###### 

Laboratory findings of the study participants

  **Laboratory characteristic**                                                            **Frequency (n=260)**   **Percentage (%)**
  ------------------------------------------- -------------------------------------------- ----------------------- --------------------
  **Serum albumin (g/L)**                     **NR in g/L (35--50)**                                                
  Mean (SD) 25.3(7.3)                                                                                              
                                              \<35                                         234                     90
  **CD4 count (cells/μl)**                                                                                          
  Mean (SD) 126.8 (161.8)                                                                                          
                                              \<200                                        163                     78.4
  **\*\*ALT level (U/L)**                     **NR in U/L (0--80)**                                                 
  Mean (SD) 17.4 (25.7)                                                                                            
                                              ≥80                                          9                       3.5
  **\*\*\*ALP level (U/L)**                   **NR in U/L (30--129)**                                               
  Mean (SD) 160.9 (140.3)                                                                                          
                                              ≥129                                         109                     41.9
  **\*\*\*\*GFR (ml/min/1.73m**^**2**^**)**   **NR in ml/min/1.73m**^**2**^**(90--120)**                            
  Mean (SD) 86.3(26.1)                                                                                             
                                              \<90                                         69                      26.5

\* SD- Standard deviation NR- Normal range \*\*ALT- Alanine transaminase \*\*\* ALP- Alkaline phosphatase \*\*\*\*GFR-Glomerular filtration rate.

Prevalence of DM and the clinical characteristics of the TB-DM co-infected participants
---------------------------------------------------------------------------------------

DM was diagnosed in 22 study participants giving a prevalence of 8.5%. Twenty participants had type 2 DM while 2 had type 1 DM. Of the 22 participants, 5 (22.7%) had a known diagnosis of DM and all had poor glycemic control (defined as RBS level \> 180 mg/dl) at baseline despite being on glucose lowering therapy. The background prevalence of DM on the medical units in the hospital during the study period was 6.4%.

The most frequent symptoms among the study participants with DM-TB co-infection were polyuria (90.9%), polydipsia (77.3%) and progressive weight loss (68.2%). The socio-demographic characteristics, category and episode of TB of the study participants did not significantly differ between the diabetic and non diabetic TB patients (Table [3](#T3){ref-type="table"}).

###### 

Bivariate analysis for the characteristics of the study participants

  **Random Blood Sugar (RBS) level in mg/dl**                                                                             
  --------------------------------------------- ------------------------ -------------------------- --------------------- -------------
  **Characteristic**                             **≥200, (n=22) n (%)**   **\<200, (n=238) n (%)**  **OR 95%CI**            **P value**
  **Age in years**                                                                                                                     
  Age≥35                                                17(6.5)                  160(61.5)          1.66(0.59-4.66)                0.33
  Age\<35                                                5(1.9)                   78(0.3)                                              
  **Gender**                                                                                                                           
  Male                                                  9(40.9)                  137(57.6)          0.51(0.21-1.24)                0.13
  Female                                                13(59.1)                  101(42.4                                             
  **Place of residence**                                                                                                               
  Urban                                                 15(68.2)                 168(70.6)          0.89(0.35-2.28)               0.813
  Rural                                                 7(31.8)                   70(29.4)                                             
  **Occupation**                                                                                                                       
  Employed                                              17(77.3)                 185(77.7)          0.97(0.34-2.76)               0.961
  Unemployed                                            5(22.7)                   53(22.3)                                             
  **Smoking status**                                                                                                                   
  Former smoker                                         3(13.6)                   63(26.5)          2.28(0.65-7.97)               0.141
  Non smoker                                            19(86.4                  175(73.5)                                             
  **HIV serology**                                                                                                                     
  **HIV positive**                                    **13(59.1)**             **195(81.5)**        **0.32(0.13-0.79)**       **0.016**
  **HIV negative**                                    **9(40.9)**               **43(18.5)**                                           
  **Category of TB**                                                                                                                   
  δPTB                                                  19(86.4)                 178(74.8)          0.46(0.13-1.64)               0.225
  §EPTB                                                 3(13.6)                   60(25.2)                                             
  **Episode of TB**                                                                                                                    
  Newly diagnosed                                      18 (81.8)                 192 (80.7)         2.13(0.61-7.5)                  0.3
  Relapsed TB                                           4(18.2)                   46(19.3)                                             
  **\*BMI, kg/m2**                                                                                                                     
  ≥17.5                                                  7(2.6)                  103(39.6)          0.61(0.24-1.6)                  0.3
  \<17.5                                                15(5.7)                  135(51.9)                                             
  **\*\*GFR,ml/min**                                                                                                                   
  GFR\<90                                                **5**                     **64**           1.25(0.44-3.53)                0.67
  GFR≥90                                                   17                       174                                                
  \*\*\***ALT in U/L**                                                                                                                 
  ALT≥80                                                   3                         6              6.1(1.4-26.36)                0.032
  ALT\<80                                                  19                       232                                                
  **CD4/mm**^**3**^                                                                                                                    
  CD4≥350                                                                                           0.82(0.1-6.7)                  0.85
  CD4\<350                                                                                                                             
  **\*\*\*\*ALP-U/L.**                                                                                                                 
  ALP≥12                                                   8                        102             0.76(0.31-1.88)                0.56
  ALP\<129                                                 14                       136                                                

SD- Standard deviation \*BMI-Body mass index \*\* GFR-Glomerular filtration rate \*\*\*ALT- Alanine transaminase \*\*\*\* ALP- Alkaline phosphatase δPTB-Pulmonary tuberculosis §EPTB-Extra pulmonary tuberculosis.

At bivariate analysis, HIV co-infection was protective of DM (OR-0.32, 95% CI 0.13-0.79, P=0.016) and raised mean ALT concentrations were associated with DM (OR-6.1, 95% CI 1.4-26.36, p=0.032). For every unit change in the ALT category there was a 1.8 unit increase in the RBS (95% CI 0.35-3.3, p=0.02).

The relationship between DM and HIV as well as that with ALT remained statistically significant on multivariate analysis (HIV: OR- 0.17 95%CI 0.06-0.51, p=0.002 and ALT: OR-11.42 95%CI 2.15-60.59, p=0.004). On multivariate analysis, for every unit change in the ALT category, there was a 2.4 unit change in the random blood sugar (95%CI=0.77-4.1, p=0.04). Other variables considered in the multivariate analysis included age, sex, episode of TB infection (relapse or new infection), BMI, category of TB and smoking, though were not statistically significant.

The diabetic TB-HIV co-infected patients had lower baseline mean CD4 counts compared to non diabetic TB-HIV co-infected patients, although this was not statistically significant (Table [4](#T4){ref-type="table"}).

###### 

Predictor variables considered for association with DM at multivariate analysis

  **Characteristic**    **Crude OR**   **95% CI**        **P value**   **Adjusted OR**   **95% CI**         **P value**
  --------------------- -------------- ----------------- ------------- ----------------- ------------------ -------------
  **HIV sero-status**   **0.32**       **(0.13-0.79)**   **0.016**     **0.17**          **(0.06-0.51)**    **0.002**
  **ALT in U/L**        **6.10**       **(1.4-26.36)**   **0.032**     **11.42**         **(2.15-60.59)**   **0.004**
  Gender                0.51           (0.21-1.26)       0.14          0.52              (0.17-1.55)        0.242
  Smoking               2.28           (0.65-7.97)       0.14          2.64              (0.57-12.2)        0.214
  TB category           0.46           (0.13-1.64)       0.225         0.56              (0.16-1.94)        0.36
  TB episode            2.13           (0.61-7.5)        0.31          0.73              (0.48-7.4)         0.36
  BMI                   0.61           (0.24-1.6)        0.3           0.59              (0.21-1.64)        0.314

Discussion
==========

This study demonstrates that DM is highly frequent among admitted TB patients in Mulago hospital, Uganda. To our knowledge, this is the first study to examine this association in Uganda, one of the high burden TB countries in SSA. The reported prevalence of DM among the TB patients of 8.5% is significantly higher than the estimated prevalence of DM among the general population in Uganda (2.2%) \[[@B4]\] and the back ground prevalence of DM on the medical units in the hospital during the study period (6.4%).

The documented prevalence of DM among TB patients in the African studies published between 1980 and 2006 varies between 2.1%-6.7% \[[@B14]-[@B17]\]. The observed prevalence of DM among TB patients in our study is comparable to that reported from Nigeria \[[@B16]\] and Tanzania \[[@B17]\] but higher than what was noted in South Africa \[[@B14]\] and Guinea Conakry \[[@B15]\].

This heterogeneity in the above results could probably be explained by the varied techniques used to diagnose DM among the TB patients and the probable effects of co morbidities like HIV. Largely, an oral glucose tolerance test (OGTT) was used in diagnosing DM in most African studies \[[@B14],[@B16],[@B17]\]. Balde et al. used a fasting capillary blood test to diagnose DM among TB patients in Guinea Conakry \[[@B15]\]. In our study, the diagnosis of DM was made basing on a random or casual capillary blood test. No particular method of diagnosing DM among TB patients has been advocated for. Either a random blood sugar (RBS), fasting blood sugar (FBS), OGTT or glycated haemoglobin (HbA1c) test can be used alone or in combination \[[@B5]\].

Similar studies from other parts of the world have reported remarkably higher prevalence of DM among TB patients. In Asia and the Middle East, the documented prevalence varies from 9.5%-44% \[[@B13],[@B18]-[@B23]\] and 11.9%-27% \[[@B24]-[@B26]\] respectively. A multi centre study done in Texas, USA and Mexico reported prevalence of 39% and 36% respectively \[[@B27]\]. This higher prevalence could probably be due to the higher background prevalence of DM in the general population in those respective countries.

Type 2 DM was the most frequent type of DM encountered among the study participants with DM-TB co-infection (90.9%). A similar observation has been documented in most similar studies \[[@B13],[@B15],[@B18]\]. This could probably be due to the higher proportions of people with type 2 DM compared to type 1 DM in most general populations.

Five (1.9%) of the study participants at enrolment had a prior diagnosis of DM and on assessment to determine the extent of glycemic control, they all had poor glycemic control which we defined as a RBS level ≥ 180 mg/dl. TB infection is often associated with a transient stress induced hyperglycemia which results into suboptimal glycemic control among diabetic patients. It usually resolves following TB therapy \[[@B28]\].

This form of reactionary hyperglycemia can also lead to over diagnosis of DM among TB patients. Studies by Alisjahbana et al. \[[@B13]\], Oluboyo et al. \[[@B16]\] and Mugusi et al. \[[@B17]\] demonstrated improvement in the glycemic status of some patients following TB treatment. However in our study, we did not perform a repeat assessment of the glycemic status among the newly diagnosed DM patients during the course of TB therapy.

HIV co-infection and raised mean serum ALT concentrations were noted to be independently associated with DM among TB patients in our study. In contrast to available literature and findings from other studies \[[@B29]-[@B33]\], HIV infection appeared protective in our study. A probable explanation for this is that most of our HIV positive patients were taking cotrimoxazole prophylaxis, a drug which has been found to cause hypoglycaemic effects in some patients \[[@B34]\]. However, this relationship between HIV and DM in our study needs to be interpreted with caution. This is because a study done in this similar setting to determine glycemic levels in patients with severe sepsis (80% of whom also had HIV infection and were on cotrimoxazole prophylaxis) revealed no statistically significant association between HIV infection and hyperglycemia (OR-0.97, 95%CI 0.57-1.62) \[[@B35]\].

Raised mean serum ALT concentrations in TB/DM patients have not been described in any similar studies. However, since majority of the study participants had HIV co-infection, an elevated mean ALT concentration of \>66 U/L prior to diagnosis of DM was noted to be significantly associated with DM among HIV infected patients in one case control study performed in an urban HIV clinic in the USA \[[@B33]\].

A raised mean serum ALT concentration is a strong predictor of insulin resistance \[[@B36]\]. It also principally reflects direct hepatocellular damage or liver dysfunction. Liver dysfunction secondary to underlying hepatitis C and hepatosteatosis have been demonstrated to be associated with DM \[[@B37]-[@B40]\].

Hepatitis C infection is associated with insulin resistance owing to an increased pro-inflammatory state and production of cytokines especially tumour necrosis factor α and interleukin 6. These inhibit transcription of the glucose transporter-4 and peroxisome proliferator --activated receptor γ. Insulin resistance results into alteration in lipid metabolism and deposition in the hepatocytes. Hepatosteatosis often develops later. Hepatitis C co-infection is also associated with autoimmune pancreatic beta cell damage leading to DM \[[@B37]-[@B40]\]. In addition to hepatitis C infection, human herpes virus type 8 (HHV-8), a highly prevalent virus among HIV infected patients that causes with kaposi sarcoma has also been demonstrated to be linked to ketosis prone type 2 DM, an atypical form of DM commonest among black Africans \[[@B41]\]. In our study however, we did not assess for presence of hepatosteatosis, hepatitis C or HHV-8 co-infection among the study participants.

Majority of the similar studies have reported increasing age, overweight or obesity \[[@B15],[@B19],[@B20],[@B27]\] and male gender \[[@B20]\] as the clinical factors associated with DM among TB patients. Sedentary lifestyle and family history of DM and obesity were also noted to be independently associated with DM in the study done in Guinea Conakry \[[@B15]\]. These clinical factors were not significantly associated with DM among our study participants.

Study limitations
-----------------

We acknowledge important limitations in our study. Only one RBS estimation was used to diagnose DM hence leading to a possibility of overestimating of the prevalence of DM among our study participants since patients with reactive hyperglycemia could have been included. Use of an OGTT could have diagnosed more patients with borderline DM.

Although the study adjusted for some of the confounding factors, the role of residual confounding factors for the association between DM and TB cannot be ruled out. In addition, due to the cross sectional nature of the study, the temporality between the TB and DM could not be ascertained.

As similar findings have been documented among TB patients in other parts of the world, we believe that our findings are generalisable and hence we recommend that patients diagnosed with TB should routinely have their blood sugar levels assessed in order to enable timely diagnosis and optimal management of DM.

Conclusion
==========

DM is a frequent co morbid condition among TB patients in Uganda. HIV co-infection and raised mean serum ALT concentrations are independently associated with DM among TB patients. We recommend routine screening for DM among TB patients in Uganda especially those with raised mean serum ALT concentrations of ≥80 U/L. Further prospective studies to examine the effects of DM on the clinical outcomes among TB-DM co-infected patients in Uganda are warranted.
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